Corrigendum to “Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review” [New Microbes New Infect] 6 (2015) 1–4]

• N. Wagner,
• C.A. Wyler-Lazarevic,
• S. Yerly,
• C. Samer,
• G. Peytavin,
• K.M. Posfay-Barbe,
• A. Calmy,
• J. Ambrosioni

Affiliations

N. Wagner

Department of Paediatrics, Switzerland

C.A. Wyler-Lazarevic

Department of Paediatrics, Switzerland

S. Yerly

Laboratory of Virology, Department of Genetics and Laboratory Medicine, Switzerland

C. Samer

Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Switzerland

G. Peytavin

Department of Clinical Pharmaco-Toxicology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France

K.M. Posfay-Barbe

Department of Paediatrics, Switzerland

A. Calmy

Division of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland

J. Ambrosioni

Division of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland